A detailed history of Connacht Asset Management LP transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Connacht Asset Management LP holds 8,204 shares of XENE stock, worth $319,135. This represents 1.72% of its overall portfolio holdings.

Number of Shares
8,204
Previous 6,165 33.07%
Holding current value
$319,135
Previous $237,000 18.14%
% of portfolio
1.72%
Previous 0.33%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$34.16 - $39.73 $69,652 - $81,009
2,039 Added 33.07%
8,204 $280,000
Q2 2023

Aug 14, 2023

SELL
$34.84 - $43.54 $7,873 - $9,840
-226 Reduced 3.54%
6,165 $237,000
Q1 2023

May 15, 2023

BUY
$33.46 - $40.35 $213,842 - $257,876
6,391 New
6,391 $228,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.42B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Connacht Asset Management LP Portfolio

Follow Connacht Asset Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connacht Asset Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Connacht Asset Management LP with notifications on news.